4//SEC Filing
Biller Scott 4
Accession 0001209191-19-014933
CIK 0001439222other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 4:02 PM ET
Size
18.3 KB
Accession
0001209191-19-014933
Insider Transaction Report
Form 4
Biller Scott
Chief Scientific Officer
Transactions
- Sale
Common stock
2019-02-27$65.00/sh−9,000$585,000→ 26,511 total - Exercise/Conversion
Stock option (right to buy)
2019-02-27−1,766→ 0 totalExercise: $0.47Exp: 2020-12-06→ Common stock (1,766 underlying) - Exercise/Conversion
Stock option (right to buy)
2019-02-27−3,080→ 11,782 totalExercise: $31.64Exp: 2024-03-04→ Common stock (3,080 underlying) - Exercise/Conversion
Common stock
2019-02-27$9.05/sh+4,154$37,594→ 32,431 total - Exercise/Conversion
Common stock
2019-02-27$0.47/sh+1,766$830→ 28,277 total - Exercise/Conversion
Common stock
2019-02-27$31.64/sh+3,080$97,451→ 35,511 total - Exercise/Conversion
Stock option (right to buy)
2019-02-27−4,154→ 0 totalExercise: $9.05Exp: 2023-04-30→ Common stock (4,154 underlying)
Holdings
- 53,059(indirect: See footnote)
Common stock
Footnotes (6)
- [F1]This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
- [F4]This option was granted on December 7, 2010. The shares underlying this option vested as to 25% of the shares upon the achievement of a performance milestone, and as to the remaining 75% in 36 equal monthly installments thereafter. The performance criteria was met on June 23, 2015.
- [F5]This option was originally granted on April 30, 2013 for the purchase of 68,181 shares of common stock. The option vests as to 50% of the underlying shares upon the achievement of a performance milestone, and as to the remaining 50% of upon the achievement of a second performance milestone. The Company's board of directors determined that the first performance milestone was achieved on December 3, 2015, resulting in the vesting of this option as to 34,091 shares. On January 26, 2017, the Company's board of directors determined that the second performance milestone was achieved, resulting in the vesting of this option as to the remaining 34,090 shares.
- [F6]This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS INC
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001581956
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 4:02 PM ET
- Size
- 18.3 KB